Group 1 - The cosmetics sector experienced a rise of 1.33% on December 31, with Shuiyang Co., Ltd. leading the gains [1] - The Shanghai Composite Index closed at 3968.84, up 0.09%, while the Shenzhen Component Index closed at 13525.02, down 0.58% [1] - Key stocks in the cosmetics sector showed varied performance, with Shuiyang Co., Ltd. closing at 23.84, up 9.56%, and Qingdao Kingking closing at 7.65, up 5.23% [1] Group 2 - The cosmetics sector saw a net inflow of 50.68 million yuan from institutional investors, while retail investors experienced a net outflow of 89.73 million yuan [2] - The stock performance of individual companies showed that Qingdao Kingking had a significant net outflow of 50.75 million yuan from institutional investors [3] - Shuiyang Co., Ltd. had a net inflow of 32.23 million yuan from institutional investors, indicating strong interest despite overall retail outflows [3]

广东丸美生物技术股份有限公司 2025年第三次临时股东会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 证券代码：603983 证券简称：丸美生物 公告编号：2025-048 一、 会议召开和出席情况 (一) 股东会召开的时间：2025 年 12 月 30 日 (二) 股东会召开的地点：广州市海珠区新港东路 69 号丸美大厦 11 楼会 议室 (三) 出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情 况： | 1、出席会议的股东和代理人人数 | 161 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 335,075,306 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | 83.5599 | | 份总数的比例（%） | | (四) 表决方式是否符合《公司法》及《公司章程》的规定，会议主持情 况等。 本次会议由公司董事会召集，采用现场投票与网络投票相结合的方式召开。 会议的召集和召开程序、出席会议人员的资格、会 ...

广东信达律师事务所 股东会法律意见书 中国 深圳 福田区 益田路 6001 号 太平金融大厦 11、12 楼 邮政编码：518038 11F/12F., TAIPING FINANCE TOWER, NO.6001 YITIAN ROAD, SHENZHEN, CHINA 电话（Tel.）：（0755）88265288 传真（Fax.）：（0755）88265537 网站（Website）：https://www.sundiallawfirm.com 广东信达律师事务所 关于广东丸美生物技术股份有限公司 2025 年第三次临时股东会的 法律意见书 1 广东信达律师事务所 股东会法律意见书 信达会字（2025）第 418 号 致：广东丸美生物技术股份有限公司 广东信达律师事务所（以下简称"信达"）接受广东丸美生物技术股份有限 公司（下称"贵公司"）的委托，指派律师参加了贵公司 2025 年第三次临时股 东会（下称"本次股东会"），并进行了必要的验证工作。现根据《中华人民共 和国公司法》（下称"《公司法》"）、《上市公司股东会规则》（下称"《股 东会规则》"）以及贵公司《公司章程》的规定，按照律师行业公认的业务标 ...

Core Viewpoint - The cosmetics sector experienced a slight increase of 0.36% on December 30, with Qingsong Co., Ltd. leading the gains. The Shanghai Composite Index closed at 3965.12, showing no change, while the Shenzhen Component Index rose by 0.49% to 13604.07 [1]. Group 1: Stock Performance - Qingsong Co., Ltd. (300132) closed at 69.8, up by 6.50%, with a trading volume of 430,400 shares and a transaction value of 366 million yuan [1]. - Marubi Biological Technology (603983) closed at 33.18, increasing by 2.60%, with a trading volume of 44,700 shares and a transaction value of 14.9 million yuan [1]. - Shuiyang Co., Ltd. (300740) closed at 21.76, up by 1.26%, with a trading volume of 160,800 shares [1]. - Other notable stocks include Shanghai Jahwa (600315) with a slight increase of 0.27% and a closing price of 22.52, and Furuida (600223) remaining unchanged at 7.35 [1]. Group 2: Capital Flow - The cosmetics sector saw a net inflow of 46.64 million yuan from institutional investors, while retail investors experienced a net outflow of 68.77 million yuan [2]. - Qingsong Co., Ltd. had a significant net inflow of 34.30 million yuan from institutional investors, while retail investors showed a net outflow of 30.07 million yuan [3]. - Shanghai Jahwa recorded a net inflow of 17.15 million yuan from institutional investors, with a net outflow of 17.20 million yuan from retail investors [3].

Group 1 - The cosmetics sector experienced a decline of 1.26% on December 29, with Shanghai Jahwa leading the drop [1] - The Shanghai Composite Index closed at 3965.28, up 0.04%, while the Shenzhen Component Index closed at 13537.1, down 0.49% [1] - Key individual stock performances in the cosmetics sector included Qingdao Kingway up 1.38% and Shanghai Jahwa down 3.06% [2] Group 2 - The net outflow of main funds in the cosmetics sector was 94.94 million yuan, while retail funds saw a net inflow of 41.59 million yuan [2] - The main fund flow for Shanghai Jahwa showed a net outflow of 1.0677 million yuan, with retail funds showing a net inflow of 2.0905 million yuan [3] - Qingdao Kingway had a significant net outflow of 24.09 million yuan from main funds, while retail funds experienced a net outflow of 23.17 million yuan [3]

Investment Rating - The report maintains an "Outperform" rating for the beauty and personal care industry, indicating a positive outlook for growth opportunities in the sector [3]. Core Insights - The report emphasizes that innovation in ingredients, particularly new materials like PDRN (Polydeoxyribonucleotide) and ECM (Extracellular Matrix), is a significant driver for growth in the beauty and medical aesthetics industry. Companies that successfully integrate these new components into their product lines are expected to enhance their growth potential and market competitiveness [5][14]. Summary by Sections 1. PDRN: A New Ingredient Driving Growth - PDRN has been validated in overseas markets for over a decade and is recognized for its effectiveness in promoting tissue regeneration and anti-inflammatory properties. The introduction of PDRN products in the medical aesthetics sector has shown a compound annual growth rate (CAGR) of 30% from 2014 to 2024 for companies like PharmaResearch, which has established a strong market presence with its Rejuran product line [5][18][32]. - The domestic market for PDRN is expected to grow significantly, with a projected revenue of approximately 330 million RMB from Q4 2024 to Q3 2025, indicating robust demand for PDRN products in China [5][20]. - The report highlights that the increasing awareness and education around PDRN among consumers, coupled with regulatory clarity and rapid supply chain development, will further drive demand in the medical aesthetics sector [5][68]. 2. ECM: Potential in Regenerative Fields - ECM is gaining attention as a promising ingredient in both medical aesthetics and cosmetics, with applications in serious medical fields already established. The report notes that the market for ECM products is still developing, with several companies beginning to explore its potential in aesthetic applications [5][24][28]. - The report suggests that the introduction of ECM products could fill existing gaps in the market, particularly in the medical aesthetics sector, where consumer education and awareness are crucial for adoption [5][24]. 3. Investment Opportunities - The report recommends focusing on companies with established pipelines for new materials, particularly in the medical aesthetics sector, such as Lepu Medical and Marubi Biotechnology, which are expected to lead in the approval and commercialization of PDRN products [5][6]. - In the cosmetics sector, brands that are quick to adopt PDRN and other innovative ingredients are likely to gain a competitive edge, with several major brands already launching PDRN-infused products in 2025 [5][6].

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Views - The retail industry is experiencing a transformation with a focus on emotional consumption and innovative product offerings, particularly in the jewelry and cosmetics sectors [6][33] - Companies like潮宏基 and毛戈平 are leveraging multi-channel strategies to enhance brand visibility and product sales, indicating a strong market presence [26][31] Summary by Sections Retail Market Overview - The retail index closed at 2462.73 points, with a weekly increase of 0.16%, underperforming the Shanghai Composite Index, which rose by 1.88% [5][15] - The retail sector has seen a year-to-date increase of 10.00%, lagging behind the Shanghai Composite Index's 18.26% rise [15][19] Company Highlights - **潮宏基**: Achieved a revenue of 62.37 billion yuan in the first three quarters of 2025, up 28.4% year-on-year, with a net profit of 3.17 billion yuan, reflecting a 0.3% increase [42] - **毛戈平**: Launched the "琉光赋活" skincare series, set to debut on January 1, 2026, focusing on high-end skincare needs [31] - **周大福**: Reported a revenue of 389.86 billion HKD for FY2026H1, a slight decrease of 1.1%, but with a net profit increase of 0.1% [39] Investment Themes - **Gold and Jewelry**: Focus on brands with differentiated product offerings and consumer insights, recommending潮宏基 and老铺黄金 as key players [6][33] - **Offline Retail**: Emphasis on companies adapting to market changes, with recommendations for永辉超市 and爱婴室 [6][33] - **Cosmetics**: Highlighting brands that innovate with emotional value and safe ingredients, recommending毛戈平 and珀莱雅 [6][34] - **Medical Aesthetics**: Targeting differentiated product manufacturers and expanding medical aesthetic chains, with recommendations for爱美客 and科笛-B [6][34]

Market Overview - The cosmetics sector experienced a slight decline of 0.13% on December 26, with Qingsong Co. leading the drop [1] - The Shanghai Composite Index closed at 3963.68, up 0.1%, while the Shenzhen Component Index closed at 13603.89, up 0.54% [1] Individual Stock Performance - Marubi Biotechnology (603983) closed at 33.09, up 0.91% with a trading volume of 23,700 shares and a turnover of 78.26 million yuan [1] - Shanghai Jahwa (600315) closed at 23.17, up 0.83% with a trading volume of 32,000 shares and a turnover of 74.08 million yuan [1] - Furuida (600223) closed at 7.39, up 0.41% with a trading volume of 55,100 shares and a turnover of 40.71 million yuan [1] - Proya Cosmetics (603605) closed at 67.92, up 0.06% with a trading volume of 27,900 shares and a turnover of 20.06 million yuan [1] - Betaini (300957) closed at 40.48, down 0.59% with a trading volume of 37,100 shares and a turnover of 151 million yuan [1] - Other notable declines include Qingsong Co. (300132) down 1.57% and Jinsong New Materials (300849) down 1.55% [2] Capital Flow Analysis - The cosmetics sector saw a net outflow of 80.47 million yuan from institutional investors, while retail investors contributed a net inflow of 70.02 million yuan [2] - The overall capital flow indicates a mixed sentiment, with institutional investors withdrawing funds while retail investors increased their positions [2] Detailed Capital Flow for Selected Stocks - Furuida (600223) had a net inflow of 7.77 million yuan from institutional investors, but a net outflow of 4.35 million yuan from retail investors [3] - Huaye Fragrance (300886) saw a net inflow of 3.30 million yuan from institutional investors, while retail investors had a net outflow of 1.01 million yuan [3] - Marubi Biotechnology (603983) experienced a net inflow of 1.22 million yuan from institutional investors, with retail investors also seeing a net outflow [3] - Qingsong Co. (300132) had a significant net outflow of 1.57 million yuan from institutional investors [3]

广东丸美生物技术股份有限公司 2025 年第三次临时股东会会议资料 广东丸美生物技术股份有限公司 2025 年第三次临时股东会 会议资料 广东丸美生物技术股份有限公司 2025 年第三次临时股东会会议资料 广东丸美生物技术股份有限公司 2025 年 12 月 30 日 1 2025 年第三次临时股东会会议须知 各位股东及股东代表： 为维护投资者的合法权益，确保广东丸美生物技术股份有限公司（以下简称"公 司"）2025 年第三次临时股东会的顺利召开，依据中国证券监督管理委员会《上市 公司股东会规则》等有关规定，制定会议须知如下： 一、公司根据《公司法》《证券法》《上市公司股东会规则》和《公司章程》的规 定，认真做好召开股东会的各项工作。 六、股东发言由会议主持人指名后进行，每位股东发言应先报告所持股份数和持 股人名称，简明扼要地阐述观点和建议，发言时间一般不超过 5 分钟，主持人可安 排公司董事或高级管理人员等回答股东提问。 七、股东发言应围绕本次会议议题进行，股东提问内容与本次股东会议题无关或 涉及公司商业秘密的，公司有权不予回应。 八、为提高会议议事效率，在就股东的问题回答结束后，即进行表决。现场会议 表决 ...

Core Viewpoint - Marubi Biotechnology (丸美生物) is planning to issue H-shares to raise funds aimed at enhancing its core strategies, including strengthening its omni-channel sales system, improving brand value, incubating new brands, enhancing R&D capabilities, optimizing the supply chain, and supplementing working capital, with the goal of improving overall competitiveness [1][2] Group 1: Company Strategy and Market Position - The company has been focused on the anti-aging skincare industry for over 20 years, leveraging synthetic biology technology and core breakthroughs in research and development, particularly in recombinant collagen products [1] - According to a Frost & Sullivan report, Marubi is the third largest beauty company in China in the recombinant collagen skincare segment, based on retail sales projected for 2024 [1] - Marubi has established an integrated R&D platform that encompasses synthetic biology, protein engineering, green chemistry, natural plant extraction, and bio-fermentation, continuously launching new ingredients and products to support business growth [1] Group 2: Fundraising and Use of Proceeds - The company has developed over 80 proprietary ingredients, including recombinant double collagen and super molecular cotton flower extract, with more than 30 achieving large-scale production as of September 30, 2025 [2] - The funds raised from the H-share issuance will be used to build a comprehensive omni-channel sales system, enhance brand value through diversified marketing activities, expand the R&D team, upgrade R&D facilities, improve supply chain capabilities, and support working capital [2] - The issuance will not change the company's control, with Dr. Sun Huaqing and Wang Xiaopu remaining the actual controllers [2] Group 3: Competitive Advantage and Future Outlook - Marubi's brand has ranked first in China's domestic eye care market for four consecutive years, while its "Lianhuo" brand ranks third among domestic foundation brands [3] - The anti-aging skincare segment is the fastest-growing sub-sector in China's skincare industry, and the company aims to leverage this growth opportunity through continued investment in core technology R&D [3] - As of September 30, 2025, the company has applied for 651 patents globally, with 265 authorized invention patents, positioning its R&D strength among the top in domestic beauty enterprises [3] - The H-share issuance is viewed as a strategic decision for long-term development, enhancing capital strength and core competitiveness, and laying a solid foundation for sustainable growth and shareholder value creation [3]